Skinvisible, Inc. (SKVI)
OTCMKTS
· Delayed Price · Currency is USD
0.2300
0.00 (0.00%)
Apr 23, 2025, 4:00 PM EDT
Skinvisible Revenue
In the year 2024, Skinvisible had annual revenue of $20.00K. Skinvisible had revenue of $5.00K in the quarter ending December 31, 2024.
Revenue
20.00K
Revenue Growth
n/a
P/S Ratio
61.14
Revenue / Employee
10.00K
Employees
2
Market Cap
1.22M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 20.00K | - | - |
Dec 31, 2023 | 20.00K | -259.30K | -92.84% |
Dec 31, 2022 | 279.30K | -384.13K | -57.90% |
Dec 31, 2021 | 663.43K | 387.87K | 140.76% |
Dec 31, 2020 | 275.56K | 232.39K | 538.36% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Cuisine Solutions | 80.48M |
Armanino Foods of Distinction | 69.40M |
ESG Inc. | 12.68M |
Huahui Education Group | 1.23M |
Crimson Wine Group | 72.99M |
Hongchang International | 2.87M |
Innovative Food Holdings | 72.13M |
Pyxus International | 2.38B |
Skinvisible News
- 3 months ago - Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies - Accesswire
- 3 months ago - Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies - Accesswire
- 7 months ago - Skinvisible Announces Article Highlighting Its Proprietary Transdermal Obesity Formulation Development - Accesswire
- 10 months ago - Promising Data on Transdermal Obesity Formulations Announced by Skinvisible - Accesswire
- 10 months ago - Skinvisible Expands Obesity Patent Application for Transdermal Delivery - Accesswire
- 1 year ago - Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome - Accesswire
- 3 years ago - Skinvisible Announces First Invisicare Delivery Technology Product to Receive U.S. FDA Acceptance of Investigational New Drug - Accesswire